Zevra Therapeutics (ZVRA) Gains from Investment Securities (2014 - 2023)
Zevra Therapeutics' (ZVRA) quarterly Gains from Investment Securities came in at $2000.0 in Q1 2023, up 100.83% YoY from $995.87 in Q1 2022, and up 106.06% on a QoQ basis from -$33000.0 in Q4 2022.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Gains from Investment Securities (2014 - 2023) Analysis & Trends
Zevra Therapeutics (ZVRA) has 10 years of Gains from Investment Securities data on file, last reported at $2000.0 in Q1 2023.
- Quarterly Gains from Investment Securities rose 100.83% year-over-year to $2000.0 in Q1 2023, while the trailing twelve-month figure through Sep 2023 was -$31000.0 (up 91.41% YoY) and the FY2022 annual result came in at -$328000.0, down 1361.54% from the prior year.
- Gains from Investment Securities climbed to $2000.0 in Q1 2023, from -$33000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $394000.0 in Q2 2021 to a low of -$1.4 million in Q3 2019.
- A 5-year average of -$124352.9 and a median of -$32000.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities jumped 13033.33% — and 2022, when it sank 903.33%.
- Tracing ZVRA's Gains from Investment Securities over 5 years: stood at -$215000.0 in 2019, then jumped by 155.35% to $119000.0 in 2020, then plunged by 155.46% to -$66000.0 in 2021, then jumped by 50.0% to -$33000.0 in 2022, then soared by 106.06% to $2000.0 in 2023.
- The last three Gains from Investment Securities figures came in at $2000.0 (Q1 2023), -$33000.0 (Q4 2022), and -$22000.0 (Q3 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | -33,000.00 |
| Sep 30, 2022 | -22,000.00 |
| Jun 30, 2022 | -32,000.00 |
| Mar 31, 2022 | -241,000.00 |
| Dec 31, 2021 | -66,000.00 |
| Sep 30, 2021 | -332,000.00 |
| Jun 30, 2021 | 394,000.00 |
| Mar 31, 2021 | 30,000.00 |
| Dec 31, 2020 | 119,000.00 |
| Sep 30, 2020 | 137,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Mar 31, 2020 | -75,000.00 |
| Dec 31, 2019 | -215,000.00 |
| Sep 30, 2019 | -1.35 Mn |
| Jun 30, 2019 | 21,000.00 |
| Mar 31, 2019 | -453,000.00 |
| Dec 31, 2018 | -5.69 Mn |
| Sep 30, 2018 | -4.47 Mn |
| Jun 30, 2018 | -5.56 Mn |